Literature DB >> 16822364

Special issues when caring for the older person with acute coronary syndromes.

Rahman Shah1, JoAnne Micale Foody.   

Abstract

Persons 75 years of age or older constitute 6% of the US population but account for more than one third of those with acute coronary syndromes (ACS). Unfortunately, most randomized clinical trials have enrolled few older persons, and, as a result, few data are available to guide clinical practice. As in younger patients, aspirin, beta-blockers, nitrates, clopidogrel, heparin, statins, and angiotensin-converting enzyme inhibitors are useful, beginning with lower doses and carefully observing the patient for symptoms of toxicity. Similarly, older patients should not be denied the benefit of reperfusion therapy and early invasive strategy because of their age. Although primary angioplasty is an optimal reperfusion strategy, thrombolytic therapy is a beneficial alternative in carefully selected older patients. Although glycoprotein IIb/IIIa inhibitors appear to be beneficial in select cases, bleeding concerns exist. Despite a growing body of evidence in support of aggressive ACS care in older persons, evidence-based therapy is underused in older patients. Continued efforts are required to improve the quality of care to this high-risk cohort of ACS patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16822364     DOI: 10.1007/s11886-006-0061-7

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  44 in total

1.  Thrombolytic therapy in older patients.

Authors:  A K Berger; M J Radford; Y Wang; H M Krumholz
Journal:  J Am Coll Cardiol       Date:  2000-08       Impact factor: 24.094

2.  Percutaneous coronary intervention outcomes in octogenarians during the stent era (National Cardiovascular Network).

Authors:  W S Weintraub; E Veledar; T Thompson; J Burnette; C Jurkovitz; E Mahoney
Journal:  Am J Cardiol       Date:  2001-12-15       Impact factor: 2.778

3.  Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE).

Authors:  Alvaro Avezum; Marcia Makdisse; Frederick Spencer; Joel M Gore; Keith A A Fox; Gilles Montalescot; Kim A Eagle; Kami White; Rajendra H Mehta; Elias Knobel; Jean-Philippe Collet
Journal:  Am Heart J       Date:  2005-01       Impact factor: 4.749

4.  Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.

Authors:  A M Lincoff; R A Harrington; R M Califf; J S Hochman; A D Guerci; E M Ohman; C J Pepine; S L Kopecky; N S Kleiman; C M Pacchiana; L G Berdan; M M Kitt; M L Simoons; E J Topol
Journal:  Circulation       Date:  2000-09-05       Impact factor: 29.690

5.  Representation of elderly persons and women in published randomized trials of acute coronary syndromes.

Authors:  P Y Lee; K P Alexander; B G Hammill; S K Pasquali; E D Peterson
Journal:  JAMA       Date:  2001-08-08       Impact factor: 56.272

6.  Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.

Authors:  E J Topol
Journal:  Lancet       Date:  2001-06-16       Impact factor: 79.321

7.  Fibrinolytic therapy in patients 75 years and older with ST-segment-elevation myocardial infarction: one-year follow-up of a large prospective cohort.

Authors:  Ulf Stenestrand; Lars Wallentin
Journal:  Arch Intern Med       Date:  2003-04-28

8.  Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study.

Authors:  W B Kannel; R D Abbott
Journal:  N Engl J Med       Date:  1984-11-01       Impact factor: 91.245

9.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction).

Authors:  Elliott M Antman; Daniel T Anbe; Paul Wayne Armstrong; Eric R Bates; Lee A Green; Mary Hand; Judith S Hochman; Harlan M Krumholz; Frederick G Kushner; Gervasio A Lamas; Charles J Mullany; Joseph P Ornato; David L Pearle; Michael A Sloan; Sidney C Smith; Joseph S Alpert; Jeffrey L Anderson; David P Faxon; Valentin Fuster; Raymond J Gibbons; Gabriel Gregoratos; Jonathan L Halperin; Loren F Hiratzka; Sharon Ann Hunt; Alice K Jacobs
Journal:  Circulation       Date:  2004-08-03       Impact factor: 29.690

Review 10.  Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.

Authors:  Ellen C Keeley; Judith A Boura; Cindy L Grines
Journal:  Lancet       Date:  2003-01-04       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.